Anavex Life Sciences (NASDAQ:AVXL) released its earnings results on Thursday. The biotechnology company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03), MarketWatch Earnings reports.
Shares of NASDAQ:AVXL traded up $0.30 during midday trading on Friday, reaching $2.34. 443,743 shares of the company’s stock traded hands, compared to its average volume of 125,428. The company has a market cap of $96.12 million, a P/E ratio of -6.00 and a beta of 2.41. Anavex Life Sciences has a one year low of $1.25 and a one year high of $4.35.
A number of research analysts have recently issued reports on AVXL shares. Roth Capital started coverage on Anavex Life Sciences in a report on Monday, January 28th. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright set a $10.00 price target on Anavex Life Sciences and gave the company a “buy” rating in a report on Wednesday, October 31st. Finally, Maxim Group set a $7.00 price target on Anavex Life Sciences and gave the company a “buy” rating in a report on Friday, October 26th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $7.40.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://dakotafinancialnews.com/2019/02/08/anavex-life-sciences-avxl-issues-quarterly-earnings-results.html.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
Recommended Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.